Consensus guidelines for the diagnosis and management of invasive aspergillosis, 2021
The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Abstract
Invasive aspergillosis (IA) in haematology/oncology patients presents as primary infection or breakthrough infection, which can become refractory to antifungal treatment and has a high associated mortality. Other emerging patient risk groups include patients in the intensive care setting with severe respiratory viral infections, including COVID‐19. These guidelines present key diagnostic and treatment recommendations in light of advances in knowledge since the previous guidelines in 2014. Culture and histological‐based methods remain central to the diagnosis of IA. There is increasing evidence for the utility of non‐culture methods employing fungal biomarkers in pre‐emptive screening for infection, as well as for IA diagnosis when used in combination. Although azole resistance appears to be uncommon in Australia, susceptibility testing of clinical Aspergillus fumigatus complex isolates is recommended. Voriconazole remains the preferred first‐line antifungal agent for treating primary IA, including for extrapulmonary disease. Recommendations for paediatric treatment broadly follow those for adults. For breakthrough and refractory IA, a change in class of antifungal agent is strongly recommended, and agents under clinical trial may need to be considered. Newer immunological‐based imaging modalities warrant further study, while surveillance for IA and antifungal resistance remain essential to informing the relevance of current treatment recommendations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Yang, X., Yu, Y., Xu, J., Shu, H., Xia, J., Liu, H., Wu, Y., Zhang, L., Yu, Z., Fang, M., et al. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30079-5 · Cited by 10,066
De Pauw, B., Walsh, T. J., Donnelly, J. P., Stevens, D. A., Edwards, J. E., Calandra, T., Pappas, P. G., Maertens, J., Lortholary, O., Kauffman, C. A., et al. (2008) · Clinical Infectious Diseases · doi:10.1086/588660 · Cited by 4,917
Voriconazole versus Amphotericin B for Primary Therapy of Invasive Aspergillosis
Herbrecht, R., Denning, D. W., Patterson, T. F., Bennett, J. E., Greene, R. E., Oestmann, J.-W., Kern, W. V., Marr, K. A., Ribaud, P., Lortholary, O., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020191 · Cited by 3,304
Patterson, T. F., Thompson, G. R., Denning, D. W., Fishman, J. A., Hadley, S., Herbrecht, R., Kontoyiannis, D. P., Marr, K. A., Morrison, V. A., Nguyen, M. H., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw326 · Cited by 2,926
Pappas, P. G., Alexander, B. D., Andes, D. R., Hadley, S., Kauffman, C. A., Freifeld, A., Anaissie, E. J., Brumble, L. M., Herwaldt, L., Ito, J., et al. (2010) · Clinical Infectious Diseases · doi:10.1086/651262 · Cited by 1,570
Kontoyiannis, D. P., Marr, K. A., Park, B. J., Alexander, B. D., Anaissie, E. J., Walsh, T. J., Ito, J., Andes, D. R., Baddley, J. W., Brown, J. M., et al. (2010) · Clinical Infectious Diseases · doi:10.1086/651263 · Cited by 1,456
Chronic pulmonary aspergillosis: rationale and clinical guidelines for diagnosis and management
Denning, D. W., Cadranel, J., Beigelman-Aubry, C., Ader, F., Chakrabarti, A., Blot, S., Ullmann, A. J., Dimopoulos, G., & Lange, C. (2016) · European Respiratory Journal · doi:10.1183/13993003.00583-2015 · Cited by 1,030
Maertens, J. A., Raad, I. I., Marr, K. A., Patterson, T. F., Kontoyiannis, D. P., Cornely, O. A., Bow, E. J., Rahav, G., Neofytos, D., Aoun, M., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01159-9 · Cited by 1,001
Pascual, A., Calandra, T., Bolay, S., Buclin, T., Bille, J., & Marchetti, O. (2008) · Clinical Infectious Diseases · doi:10.1086/524669 · Cited by 887
Schauwvlieghe, A. F. A. D., Rijnders, B. J. A., Philips, N., Verwijs, R., Vanderbeke, L., Van Tienen, C., Lagrou, K., Verweij, P. E., Van de Veerdonk, F. L., Gommers, D., et al. (2018) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(18)30274-1 · Cited by 886
Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis
Denning, D. W., Ribaud, P., Milpied, N., Caillot, D., Herbrecht, R., Thiel, E., Haas, A., Ruhnke, M., & Lode, H. (2002) · Clinical Infectious Diseases · doi:10.1086/324620 · Cited by 844
Ostrosky-Zeichner, L., Alexander, B. D., Kett, D. H., Vazquez, J., Pappas, P. G., Saeki, F., Ketchum, P. A., Wingard, J., Schiff, R., Tamura, H., et al. (2005) · Clinical Infectious Diseases · doi:10.1086/432470 · Cited by 669
Verweij, P. E., Chowdhary, A., Melchers, W. J. G., & Meis, J. F. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/civ885 · Cited by 561
Invasive aspergillosis in critically ill patients without malignancy
Meersseman, W., Vandecasteele, S. J., Wilmer, A., Verbeken, E., Peetermans, W. E., & Van Wijngaerden, E. (2004) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200401-093oc · Cited by 547
COVID-19 Associated Pulmonary Aspergillosis
Koehler, P., Cornely, O. A., Böttiger, B. W., Dusse, F., Eichenauer, D. A., Fuchs, F., Hallek, M., Jung, N., Klein, F., Persigehl, T., et al. (2020) · Mycoses · doi:10.1111/myc.13096 · Cited by 547
-D-Glucan Assay for the Diagnosis of Invasive Fungal Infections: A Meta-analysis
Karageorgopoulos, D. E., Vouloumanou, E. K., Ntziora, F., Michalopoulos, A., Rafailidis, P. I., & Falagas, M. E. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/ciq206 · Cited by 538
Combination Antifungal Therapy for Invasive Aspergillosis: A Randomized Trial
Marr, K. A., Schlamm, H. T., Herbrecht, R., Rottinghaus, S. T., Bow, E. J., Cornely, O. A., Heinz, W. J., Jagannatha, S., Koh, L. P., Kontoyiannis, D. P., et al. (2015) · Annals of Internal Medicine · doi:10.7326/m13-2508 · Cited by 514
Possible Environmental Origin of Resistance of Aspergillus fumigatus to Medical Triazoles
Snelders, E., Huis in 't Veld, R. A. G., Rijs, A. J. M. M., Kema, G. H. J., Melchers, W. J. G., & Verweij, P. E. (2009) · Applied and Environmental Microbiology · doi:10.1128/aem.00231-09 · Cited by 423
Prospective Multicenter International Surveillance of Azole Resistance in Aspergillus fumigatus
van der Linden, J. W. M., Arendrup, M. C., Warris, A., Lagrou, K., Pelloux, H., Hauser, P. M., Chryssanthou, E., Mellado, E., Kidd, S. E., Tortorano, A. M., et al. (2015) · Emerging Infectious Diseases · doi:10.3201/eid2106.140717 · Cited by 371
Use of PCR for diagnosis of invasive aspergillosis: systematic review and meta-analysis
Mengoli, C., Cruciani, M., Barnes, R. A., Loeffler, J., & Donnelly, J. P. (2009) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(09)70019-2 · Cited by 354
van der Linden, J. W. M., Camps, S. M. T., Kampinga, G. A., Arends, J. P. A., Debets-Ossenkopp, Y. J., Haas, P. J. A., Rijnders, B. J. A., Kuijper, E. J., van Tiel, F. H., Varga, J., et al. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cit320 · Cited by 342
Factors associated with mortality in transplant patients with invasive aspergillosis
Baddley, J. W., Andes, D. R., Marr, K. A., Kontoyiannis, D. P., Alexander, B. D., Kauffman, C. A., Oster, R. A., Anaissie, E. J., Walsh, T. J., Schuster, M. G., et al. (2010) · Clinical Infectious Diseases · doi:10.1086/652768 · Cited by 303
F901318 represents a novel class of antifungal drug that inhibits dihydroorotate dehydrogenase
Oliver, J. D., Sibley, G. E. M., Beckmann, N., Dobb, K. S., Slater, M. J., McEntee, L., du Pré, S., Livermore, J., Bromley, M. J., Wiederhold, N. P., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1608304113 · Cited by 289
The GRADE system for rating clinical guidelines
Kavanagh, B. P. (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000094 · Cited by 246
Hoenigl, M., Prattes, J., Spiess, B., Wagner, J., Prueller, F., Raggam, R. B., Posch, V., Duettmann, W., Hoenigl, K., Wölfler, A., et al. (2014) · Journal of Clinical Microbiology · doi:10.1128/jcm.00467-14 · Cited by 233
Caillot, D., Thiébaut, A., Herbrecht, R., de Botton, S., Pigneux, A., Bernard, F., Larché, J., Monchecourt, F., Alfandari, S., & Mahi, L. (2007) · Cancer · doi:10.1002/cncr.23109 · Cited by 190
Miceli, M. H., Maertens, J., Buvé, K., Grazziutti, M., Woods, G., Rahman, M., Barlogie, B., & Anaissie, E. J. (2007) · Cancer · doi:10.1002/cncr.22738 · Cited by 163
Safety and pharmacokinetics of CD101 IV, a novel echinocandin, in healthy adults
Sandison, T., Ong, V., Lee, J., & Thye, D. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01627-16 · Cited by 161
Viscoli, C., Herbrecht, R., Akan, H., Baila, L., Sonet, A., Gallamini, A., Giagounidis, A., Marchetti, O., Martino, R., Meert, L., et al. (2009) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkp355 · Cited by 154
Hata, K., Horii, T., Miyazaki, M., Watanabe, N.-A., Okubo, M., Sonoda, J., Nakamoto, K., Tanaka, K., Shirotori, S., Murai, N., et al. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00366-11 · Cited by 149
Herbrecht, R., Maertens, J., Baila, L., Aoun, M., Heinz, W., Martino, R., Schwartz, S., Ullmann, A. J., Meert, L., Paesmans, M., et al. (2010) · Bone Marrow Transplantation · doi:10.1038/bmt.2009.334 · Cited by 149
The antifungal arsenal: alternative drugs and future targets
Wiederhold, N. P. (2018) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2017.09.002 · Cited by 149
Lionakis, M. S., Lewis, R. E., & Kontoyiannis, D. P. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/ciy473 · Cited by 145
White, P. L., Barnes, R. A., Springer, J., Klingspor, L., Cuenca-Estrella, M., Morton, C. O., Lagrou, K., Bretagne, S., Melchers, W. J. G., Mengoli, C., et al. (2015) · Journal of Clinical Microbiology · doi:10.1128/jcm.00905-15 · Cited by 140
ImmunoPET/MR imaging allows specific detection of Aspergillus fumigatus lung infection in vivo
Rolle, A.-M., Hasenberg, M., Thornton, C. R., Solouk-Saran, D., Männ, L., Weski, J., Maurer, A., Fischer, E., Spycher, P. R., Schibli, R., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1518836113 · Cited by 134
Heng, S. C., Morrissey, O., Chen, S. C.-A., Thursky, K., Manser, R. L., Nation, R. L., Kong, D. C.-M., & Slavin, M. (2015) · Critical Reviews in Microbiology · doi:10.3109/1040841x.2013.804033 · Cited by 133
Self-citationBreakthrough Fungal Infections in Patients With Leukemia Receiving Isavuconazole
Rausch, C. R., DiPippo, A. J., Bose, P., & Kontoyiannis, D. P. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/ciy406 · Cited by 107
T-2307 Causes Collapse of Mitochondrial Membrane Potential in Yeast
Shibata, T., Takahashi, T., Yamada, E., Kimura, A., Nishikawa, H., Hayakawa, H., Nomura, N., & Mitsuyama, J. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.05954-11 · Cited by 99
Pfaller, M. A., Messer, S. A., Motyl, M. R., Jones, R. N., & Castanheira, M. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01588-12 · Cited by 98
Phase II Dose Escalation Study of Caspofungin for Invasive Aspergillosis
Cornely, O. A., Vehreschild, J. J., Vehreschild, M. J. G. T., Würthwein, G., Arenz, D., Schwartz, S., Heussel, C. P., Silling, G., Mahne, M., Franklin, J., et al. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.05134-11 · Cited by 93
Stanzani, M., Sassi, C., Lewis, R. E., Tolomelli, G., Bazzocchi, A., Cavo, M., Vianelli, N., & Battista, G. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ154 · Cited by 91
Ghannoum, M., Long, L., Larkin, E. L., Isham, N., Sherif, R., Borroto-Esoda, K., Barat, S., & Angulo, D. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00244-18 · Cited by 80
Pfaller, M. A., Huband, M. D., Flamm, R. K., Bien, P. A., & Castanheira, M. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00840-19 · Cited by 80
Diagnostic accuracy of a novel lateral-flow device in invasive aspergillosis: a meta-analysis
Pan, Z., Fu, M., Zhang, J., Zhou, H., Fu, Y., & Zhou, J. (2015) · Journal of Medical Microbiology · doi:10.1099/jmm.0.000092 · Cited by 76
Galactomannan and 1,3-β-d-Glucan Testing for the Diagnosis of Invasive Aspergillosis
Lamoth, F. (2016) · Journal of Fungi · doi:10.3390/jof2030022 · Cited by 76
Winston, D. J., Bartoni, K., Territo, M. C., & Schiller, G. J. (2011) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2010.04.017 · Cited by 73
Diagnosis of aspergillosis by PCR: Clinical considerations and technical tips
Barnes, R. A., White, P. L., Morton, C. O., Rogers, T. R., Cruciani, M., Loeffler, J., & Donnelly, J. P. (2018) · Medical Mycology · doi:10.1093/mmy/myx091 · Cited by 68
Rath, P.-M., & Steinmann, J. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.00740 · Cited by 57
Katragkou, A., McCarthy, M., Meletiadis, J., Petraitis, V., Moradi, P. W., Strauss, G. E., Fouant, M. M., Kovanda, L. L., Petraitiene, R., Roilides, E., et al. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.03261-14 · Cited by 42
Seyedmousavi, S., Meletiadis, J., Melchers, W. J. G., Rijs, A. J. M. M., Mouton, J. W., & Verweij, P. E. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00980-12 · Cited by 38
Hammarström, H., Stjärne Aspelund, A., Christensson, B., Heußel, C. P., Isaksson, J., Kondori, N., Larsson, L., Markowicz, P., Richter, J., Wennerås, C., et al. (2018) · Mycoses · doi:10.1111/myc.12773 · Cited by 15
Cited by
Fungal infections in immunocompromised critically ill patients
Garnacho-Montero, J., Barrero-García, I., & León-Moya, C. (2024) · Journal of Intensive Medicine · doi:10.1016/j.jointm.2024.01.005 · Cited by 56
How do I manage refractory invasive pulmonary aspergillosis
Vergidis, P., Sendi, P., Alkhateeb, H. B., & Nguyen, M. H. (2024) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2024.01.015 · Cited by 12
Metadata
- Authors
- Douglas, A. P., Smibert, O. C., Bajel, A., Halliday, C. L., Lavee, O., McMullan, B., Yong, M. K., van Hal, S. J., Chen, S. C. ‐., & the Australasian Antifungal Guidelines Steering Committee
- Venue
- Internal Medicine Journal
- Publisher
- Wiley
- Published
- 2021-11
- Volume
- 51
- Issue
- S7
- Pages
- 143-176
- ISSN
- 1444-0903 (ISSN-L)
- 1445-5994
- OpenAlex
- W4200237499
- Cited by
- 179
- References
- 51
- FWCI
- 7.48
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.